Intravitreal steroid versus macular laser for treatment of diabetic macular edema

Current Diabetes Reports

Volumn 9, Issue 4, 2009, Pages 272-276

  Gunther, Jonathan ^b   Ip, Michael ^a  

^a University of Wisconsin Health   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; PEGAPTANIB; TRIAMCINOLONE; VASCULOTROPIN ANTIBODY;

CLINICAL TRIAL; CORTICOSTEROID THERAPY; DIABETIC MACULAR EDEMA; DRUG APPROVAL; DRUG CHOICE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG IMPLANT; DRUG SAFETY; GOLD STANDARD; HUMAN; INTERMETHOD COMPARISON; INTRAOCULAR PRESSURE; LASER COAGULATION; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY;

DIABETIC RETINOPATHY; DRUG ADMINISTRATION ROUTES; HUMANS; LASERS; MACULAR EDEMA; STEROIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67849114453     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-009-0042-5     Document Type: Review

References (24)

1. American Diabetes AssociationH Diabetes statistics. Available at: http://www.diabetes.org/diabetes-statistics.jsp. Accessed June 13, 2008.
2. Centers for Disease Control and Prevention: Blindness caused by diabetes: Massachusetts, 1987-1994. MMWR Morb Mortal Wkly Rep 1996, 45:937-941.
3. Klein R, Klein B, Moss S, et al.: The Wisconsin Epidemiologic Study of Diabetic Retinopathy, IV: Diabetic macular edema. Ophthalmology 1984, 91:1464-1474
4. Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema: ETDRS report number 4. Int Ophthalmol Clin 1987, 27:265-272.
5. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977-986.
6. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
7. Stratton IM, Cull CA, Adler AI, et al.: Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006, 49:1761-1769.
8. Hsu J: Drug delivery methods for posterior segment disease. Curr Opin Ophthalmol 2007, 18:235-239.
9. Martidis A, Duker JS, Greenberg PB, et al.: Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002, 109:920-927.
10. Lewis H, Abrams GW, Blumenkranz MS, Campo RV: Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 1992, 99:753-759.
11. Cunningham ET Jr, Adamis AP, Altaweel M, et al.: Macugen Diabetic Retinopathy Study Group: A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005, 112:1747-1757.
12. Diabetic Retinopathy Clinical Research Network: A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007, 114:1860-1867.
13. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1985, 103:1796-1806.
14. Antcliff RJ, Marshall J: The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 1999, 14:223-232.
15. Qaum T, Xu Q, Joussen AM, et al.: VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Visual Sci 2001, 42:2408-2413.
16. Graham RO, Peyman GA: Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch Ophthalmol 1974, 92:149-154.
17. Beer PM, Bakri SJ, Singh RJ, et al.: Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003, 110:681-686.
18. Ciulla TA, Walker JD, Fong DS, Criswell MH: Corticosteroids in posterior segment disease: An update on new delivery systems and new indications. Curr Opin Ophthalmol 2004, 15:211-220.
19. Grover D, Li TJ, Chong CC: Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev 2008, 23: CD005656.
20. Diabetic Retinopathy Clinical Research Network: A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008, 115:1447-1449.
21. Cheng CK, Berger AS, Pearson PA, et al.: Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis. Invest Ophthalmol Vis Sci 1995, 36:44-53.
22. Pearson PA, Bevy B; Fluconolone Acetonide Implant Study Group: Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 2-year results of a multi-center clinical trial. Presented at Association for Research in Vision and Ophthalmology Annual Meeting. Fort Lauderdale, FL; May 1-5, 2005.
23. Berger AS, Cheng CK, Pearson PA, et al.: Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1996, 37:2318-2325.
24. McMahon G: VEGF receptor signaling in tumor angiogenesis. Oncologist 2000, 5(Suppl1): 3-10.